These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33581643)

  • 1. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
    EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
    Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
    Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
    Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
    Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
    Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
    Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
    Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
    Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA; Schneider P; Hulleman E; de Boer J; Williams O; Pieters R; Stam RW
    Leukemia; 2012 Jun; 26(6):1255-65. PubMed ID: 22282267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
    Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
    Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
    Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
    Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
    Sison EA; Rau RE; McIntyre E; Li L; Small D; Brown P
    Br J Haematol; 2013 Mar; 160(6):785-97. PubMed ID: 23294096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
    Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
    Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
    Albouhair S; Morgado E; Lavau C
    PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.